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R/bioconductorThe data here described pertain to the article by Pojo et al. (2015) [10] titled “A transcriptomic signature medi-
ated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide” (Pojo
et al., 2015 [10]). HOX genes are part of the homeobox gene family, which encodes transcription factors crucial
during embryonic development (Grier et al., 2005; Pearson et al., 2005 [6,9]) and also in postdevelopmental reg-
ulation (Neville et al., 2002; Yamamoto et al., 2003; Takahashi et al., 2004; Morgan 2006 [8,14,13,7]). Alterations
interfering with the regulation of these genes may lead to tumorigenesis in adults. Due to their contributions in
the control of important cellular processes, the deregulation of HOX genes is ultimately correlated with cancer
treatment failure and patients' poor prognosis (Golub et al., 1999; Abdel-Fattah et al., 2006 [5,1]; Costa et al.,
2010 [4]; Pojo et al., 2015 [10]). Recently, our studies showed that HOXA9 overexpression is associated with
poor prognosis in patients with glioblastoma (GBM), the most common and most malignant primary brain
tumor. Mechanistically, HOXA9 is associated with resistance to chemotherapy and with pro-proliferative, pro-
invasive and anti-apoptotic features (Costa et al., 2010 [4]; Pojo et al., 2015 [10]) in GBM in vitro models. Since
HOXA9 is a transcription factor, its target genes can be the true biological effectors of its aggressiveness. In this
context, whole genome Agilent's microarrays were used to obtain the full transcriptome of HOXA9 in a variety
of GBM cell models, including human immortalized astrocytes, established GBM cell lines, and GBM patient-
derived cell cultures. Here, we provide detailed methods, including experimental design and microarray data
analyses, which can be accessed in Gene Expression Omnibus (GEO) under the accession number GSE56517. Ad-
ditional interpretation of the data is included and supplemented in (Pojo et al., 2015 [10]).
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).es Research Institute (ICVS),
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2. Experimental design, materials and methods
2.1. Tissue culture
For this study, 4 different cell lines were used: 2 established human
glioblastoma (GBM) cell lines, U87MG and U251MG, purchased from
American TypeCulture Collection (ATCC®); 1 cell line of human immor-
talized astrocytes, hTERT/E6/E7, kindly originally supplied byDr. Russell
Pieper; and 1 primary GBMculture, GBML18, established in our lab from
a clinical specimen. All cell lines were cultured in Dulbecco's Modiﬁed
Eagle Medium (DMEM; Gibco®) supplemented with 10% fetal bovine
serum (FBS; Biochrom GmbH) and 1% penicillin–streptomycinthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
RNA purity and quality assessment for microarray experiments
Sample Nanodrop Bioanalyzer
A260/280a A260/230a RINb
hTERT/E6/E7 Control #1 2.12 1.90 9.1
HOXA9 #1 2.11 1.89 9.6
Control #2 2.10 2.03 9.9
HOXA9 #2 2.09 2.17 9.4
Control #3 2.10 2.22 9.3
HOXA9 #3 2.07 2.19 9.6
U87MG Control #1 2.07 2.16 9.6
HOXA9 #1 2.09 1.91 9.5
Control #2 2.10 2.16 9.3
HOXA9 #2 2.08 1.87 9.1
Control #3 2.11 2.17 9.4
HOXA9 #3 2.12 2.20 9.5
U251 shCtrl #1 2.09 2.22 9.1
shHOXA9 #1 2.11 2.03 9.3
shCtrl #2 2.08 2.02 9.5
shHOXA9 #2 2.09 2.09 9.4
shCtrl #3 2.09 1.94 9.6
shHOXA9 #3 2.10 2.06 9.1
GBML18 shCtrl #1 2.05 1.99 9.9
shHOXA9 #1 2.10 2.05 9.6
shCtrl #2 2.07 1.81 8.0
shHOXA9 #2 2.04 2.13 9.6
shCtrl #3 2.14 2.23 9.6
shHOXA9 #3 2.13 2.18 9.8
a Nucleic acid is detected at 260nm,whereas proteins, salts and solvents are detected at
280 and 230 nm. Thus, ratios demonstrate if the RNA is devoid of these contaminants. For
microarray experiments, ratios should be ≥1.8;
b RIN=RNA integrity number, and provides a quantitative value for RNA integrity that
facilitates the standardization of quality interpretation. For microarray experiments, RIN
should be ≥7.
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37 °C and 5% (v/v) CO2.
2.2. Cell transfections and transductions
U87MG and hTERT/E6/E7 cells, which do not express detectable
levels of HOXA9 mRNA, were previously retrovirally infected with
murine stem cell virus (MSCV) containing the HOXA9 coding region
to overexpress this gene (U87MG-HOXA9 and hTERT/E6/E7-HOXA9)
or with an empty vector (U87MG-MSCV and hTERT/E6/E7-MSCV,
control) [4]. Selection of transfected cells was performed using
500 ng/μl of G418 (Sigma-Aldrich®). U251MG and GBML18 cells,
which present high levels of HOXA9 mRNA, were also previously
transfected with a pGFP-V-RS plasmid (TG307647, clones GI330583
and GI330584; Origene Technologies, Inc.) containing HOXA9-speciﬁc
shRNAs (U251-shHOXA9 and GBML18-shHOXA9) or non-effective
shRNA sequences (U251-shCtrl and GBML18-shCtrl) [10]. Selection of
transfected cells was performed for 3-weeks, using 0.5 μg/ml of
puromycin (Santa Cruz Biotechnology®).
2.3. RNA isolation, puriﬁcation and cDNA quality control analysis
Total RNAwas isolated from 8 × 105–1 × 106 exponentially growing
cells from a T75-ﬂask. The TRIzol method (Invitrogen™) was used to
extract the total cellular RNA from the 8 cell lines previously obtained
(3 replicates from each cell line). Extracted RNA was puriﬁed using
the RNeasy PlusMicro kit (Qiagen®) and quantiﬁed using theNanodrop
2000 (under the Nucleic Acid option; Thermo Scientiﬁc, Inc.; Table 1).
RNA quantiﬁcation, integrity and purity were also validated using the
Agilent 2100 bioanalyzer (Agilent Technologies; Table 1). All RNA
samples presented A260/A280 ratios above 1.8, electropherograms
with 2 distinct peaks, corresponding to the 18S and 28S ribosomal
RNA, and RNA integrity numbers (RIN) above 8, as recommended for
microarray analysis.
To validate that the obtained samples were a good model of HOXA9
mRNA levels modulation, HOXA9 overexpression or silencing was
conﬁrmed. To do so, 1 μg of total RNA was reverse transcribed using
the High Capacity cDNA Reverse Transcriptase kit (Alfagene®), and
HOXA9 quantitative PCR was performed. This cDNA was further used
to validate the results obtained by microarrays.
2.4. Microarray experiments and gene expression analysis
2.4.1. cRNA preparation, labeling, puriﬁcation and quality control analysis
Complementary RNA (cRNA) was obtained using the Low Input
Quick Amp Labeling kit, One-Color (Agilent Technologies) using
200 ng of the total RNA. RNA samples were labeled with Cyanine 3-
CTP and ampliﬁed together with Agilent One Color Spike-In controls,
which were used as positive controls to monitor the ampliﬁcation,
labeling and microarray scanning. Labeled/ampliﬁed RNA was puriﬁed
using the RNeasy Mini Kit (Qiagen®) according to the manufacturer's
instructions. Nanodrop 2000 (under the Microarray measurement
option; Thermo Scientiﬁc, Inc.) was used to obtain the cRNA and the
Cyanine 3 dye concentrations, and to verify the quality of the cRNA
(A260/280 ratio; Table 2). All samples presented A260/280 ratios
between 2.14 and 2.33, cRNA yield N6.08 and speciﬁc activity N8.1 (rec-
ommended to be above 1.8, 1.65 and 6, respectively).
2.4.2. Hybridization and washing
Labeled cRNA (1.65 μg for all conditions)wasmixed according to the
manufacturer's protocol and hybridized in a Whole Human Genome
Microarray (G4112F, 4x44K; Agilent Technologies) at 65 °C for 17 h,
under 10 rpm using a hybridization rotator (Agilent Technologies).
After hybridization, slides were disassembled in Wash Buffer 1 and
washed once with Wash Buffer 1 at room temperature and once withWash Buffer 2 pre-warmed overnight at 37 °C according to the
manufacturer's instructions.
2.4.3. Scanning and feature extraction
Slideswere immediately scanned using theDNAMicroarray Scanner
with SureScan High-Resolution Technology (Agilent Technologies)
using 5 different Green PMT gains (100%, 80%, 60%, 40% and 20%). The
feature extraction was performed using the grid 014850_D_20070207
and the protocol GE1_107_Sep09 from Agilent. To choose the best
scanning, several parameters of the feature extraction were taken into
account, such as the number of saturated spikes and probes, the shape
of the histogram of signals plot, the Agilent spike-in plot and the
evaluation metrics. Scannings with lower number or no saturated
spikes and probes, with higher number of good metrics and with the
better histogram shape and spike-in plot were used for subsequent
analyses.
2.5. R workﬂow for data processing and analysis
For gene expression microarray data processing and analysis, the
limma [11] and hgug4112a.db [3] packages of the Bioconductor software
platform (http://www.bioconductor.org) were used. The complete
script run for each cell line is available in the Supplementary material,
being here given some excerpts to illustrate the main data processing
and analysis steps.
2.5.1. Pre-processing data
After loading the microarrays raw data, a pre-processing was
performed through background correction (using the normexp
method), normalization between arrays using quantile normalization
and log2 transformation. Probes representing control spots were
removed, keeping only the ones with status equal to “Gene”. The
expression values for replicated probes with the same ProbeName
Table 2
cRNA quality, yield and speciﬁc activity assessment for microarray experiments
Sample Nanodrop
A260/280a [Cyanine 3 dye] (pmol/μl) [cRNA] (ng/μl) cRNA yieldb (μg) Speciﬁc activityc
hTERT/E6/E7 Control #1 2.33 3.5 387.9 11.6 9.0
HOXA9 #1 2.30 4.8 487.4 14.6 9.9
Control #2 2.23 7.2 551.7 16.6 13.1
HOXA9 #2 2.23 7.0 552.3 16.6 12.7
Control #3 2.24 5.4 445.9 13.4 12.0
HOXA9 #3 2.22 5.6 457.9 13.7 12.1
U87MG Control #1 2.30 3.6 402.6 12.1 8.90
HOXA9 #1 2.32 2.8 348.4 10.5 8.1
Control #2 2.27 5.8 383.8 11.5 15.2
HOXA9 #2 2.26 7.2 476.8 14.3 15.2
Control #3 2.17 9.4 558.5 16.8 16.9
HOXA9 #3 2.23 8.5 555.4 16.7 15.3
U251 shCtrl #1 2.24 8.7 261.4 7.84 33.3
shHOXA9 #1 2.21 9.9 299.0 8.97 33.1
shCtrl #2 2.14 6.1 213.6 6.41 28.6
shHOXA9 #2 2.18 7.5 237.2 7.12 31.6
shCtrl #3 2.20 12.1 266.7 8.00 45.4
shHOXA9 #3 2.22 10.1 202.8 6.08 49.8
GBML18 shCtrl #1 2.22 5.8 226.9 6.81 25.6
shHOXA9 #1 2.22 9.5 367.6 11.0 25.8
shCtrl #2 2.18 5.1 205.0 6.15 24.9
shHOXA9 #2 2.24 5.8 245.1 7.35 23.7
shCtrl #3 2.22 10.8 306.3 9.19 35.3
shHOXA9 #3 2.20 8.8 262.4 7.87 33.5
a Nucleic acid is detected at 260 nm, whereas proteins, salts and solvents are detected at 280 and 230 nm.
b cRNA yield = ([cRNA] × elution volume) / 1000; should be N1.65.
c Speciﬁc activity = ([Cy3] / [cRNA]) × 1000; should be N6.
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was run for all cell lines. The last line in the script is used to save ﬁles
with processed data to be submitted to GEO.RG = read.maimages(targets, columns =…)
RG = backgroundCorrect(RG, method="normexp", offset=1)
RG$G = normalizeBetweenArrays(RG$G, method="quantile")
RG$G = log2(RG$G)
spottypes = readSpotTypes();
RG$genes$Status = controlStatus(spottypes,RG)
i = RG$genes$Status=="Gene"
RG.nocontrol = RG[i,]
E = new("MAList", list(targets=RG.nocontrol$targets,
genes=RG.nocontrol$genes, source=RG.nocontrol$source,
M=RG.nocontrol$Gb, A=RG.nocontrol$G))
E.avg = avereps(E, ID=E$genes$ProbeName)
write.table(E.avg$A, "processed-cellLine.csv", sep = ",")
2.5.2. Annotation
The mapping between probe identiﬁers and gene symbols was
done using the annotation provided by Agilent (http://www.chem.
agilent.com/cag/bsp/gene_lists.asp) and the hgug4112a.db annota-
tion package from Bioconductor [3], which provides detailed infor-
mation about the hgug4112a platform. For each probe identiﬁer,
the consensus gene symbol and description were retrieved from
Bioconductor packages if the annotation exists, otherwise the
Agilent annotation was assumed.
2.5.3. Differential expression
To ﬁnd the differentially expressed transcripts between each pair
of conditions for a given cell line (HOXA9-high vs HOXA9-lowexpressing cells), the lmFit function from the limma Bioconductor
package was used to ﬁt a linear model. Next, relevant statistics were
calculated using the Empirical Bayes method. Finally, the transcripts
were ranked according to their adjusted p-values, where false discovery
rates were controlled by the BH (Benjamini and Hochberg) method [2]
to address the issues related to multiple testing. Signiﬁcance was
considered for adjusted p-values b 0.05.f= factor(targets$Condition, levels=unique(targets$Condition))
design = model.matrix(~0 + f)
colnames(design) = levels(f)
contrast.matrix = makeContrasts("A_HOXA9-A_control",
levels=design)
fit = lmFit(E.avg$A, design)
fit2 = contrasts.fit(fit, contrast.matrix)
fit2 = eBayes(fit2)
output = topTable(fit2, adjust="BH", coef="A_HOXA9-
A_control",
genelist=E.avg$genes, number=5000, p.value=0.05)
output_allgenes = topTable(fit2, adjust="BH",
coef="A_HOXA9-A_control",
genelist=E.avg$genes, number=41000)2.5.4. Intersection
The results of differential expression for each paired cell line
(hTERT/E6/E7-MSCV vs. hTERT/E6/E7-HOXA9; U87MG-MSCV vs.
U87MG-HOXA9, U251-shCtrl vs. U251-shHOXA9, and GBML18-shCtrl
vs. GBML18-shHOXA9)were used toﬁnd transcripts consistently differ-
entially expressed in all cell lines, by computing the intersection of
these sets.
Fig. 1. A) Graph representing the number of differentially expressed transcripts in all tested GBM cell models. Transcripts upregulated and downregulated are those whose expression is
signiﬁcantly increased or decreased, respectively, in the presence ofHOXA9. B) Venn diagram summarizing the number of differentially expressed transcripts uponHOXA9modulation in
each cell line. In each area, the total number of transcripts within each intersection is represented.
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underCellLineA= output[output$logFC b 0,]
#intersection of overexpression genes from 2 cell lines
intersectOver = intersect(rownames(overCellLineA),
rownames(overCellLineB))
over = output[intersectOver,1:8]
over$p.value.A = output[intersectOver,13]
over$p.value.B = output_B[intersectOver,13]
over$logFC.A = output[intersectOver,9]
over$logFC.B = output_B[intersectOver,9]
2.6. Validation of microarray data by PCR
After the identiﬁcation of the differentially expressed genes due to
HOXA9 modulation, reverse transcriptase PCR (RT-PCR or qRT-PCR)
analyses were performed to validate the microarray data in a subset of
the differentially expressed target genes [10]. Speciﬁcally, selected
genes for validation were RAC2, CXCL1, NDRG1 and TOX2 for hTERT/
E6/E7 cells; ICAM2, BAMBI, ANGPT2 and PDGFRB for U87MG cells;
TOX2, NDRG1, RAC2 and NPR3 for GBML18 cells; and C10orf10, PDGFRB,
DKK1 and SOX2 for U251MG cells.
2.7. Functional enrichment analysis
As reported in [10], due to HOXA9 expression (GEO accession num-
ber GSE56517), a total of 417 probes were signiﬁcantly differentially
expressed in hTERT/E6/E7 cells (166 upregulated and 251 downregulat-
ed); 3454 probes in U87MG cells (1537 upregulated and 1917 down-
regulated); 2452 probes in U251MG cells (1301 upregulated and 1151
downregulated); and 5886 probes in GBML18 patient-derived primary
cells (2802 upregulated and 3084 downregulated; Fig. 1A). In this
context, GBML18 cells were the ones with the highest number of differ-
entially expressed transcripts, followed by U87MG, U251MG and
hTERT/E6/E7. The genes EMILIN2 (upregulated in the presence of
HOXA9), andMME,DIRAS1 andAGPAT3 (downregulated in the presence
of HOXA9), whose roles in glioma were not yet studied, were common
to the 4 GBM models (Fig. 1B). Even though, the number of genes con-
sistently regulated by HOXA9 increases when comparing only the GBM
cells (57 common transcripts; 17 upregulated and 40 downregulated).
These results suggest that the transcriptome of HOXA9 is cell-type
dependent.
In order to integrate the differentially-expressed genes in biological-
ly relevant groups, they were used for Database for Annotation, Visual-
ization and Integrated Discovery (DAVID) analyses and displayed inKEGG, GO, or Reactome pathways, or used for gene set enrichment
analysis (GSEA; http://www.broad.mit.edu/gsea/). For GSEA analysis
[12], gene sets databases from MSigDB C2 collection version 3 were
used (available online). The permutation type used was “gene sets”,
while the default option was used for all other parameters. Only results
with a p-value b 0.05 (for DAVID) or a false discovery rate b 0.25 (for
GSEA) were considered signiﬁcant. The obtained results were already
published in [10]. Brieﬂy, relevant pathways related to cellular adhesion
and migration, cell cycle, DNA repair and replication, RNA processing,
stem-cell phenotype, vasculature development, and immune-related
pathways were shown to be enriched in the HOXA9 transcriptome.
These features are known as important cancer hallmarks that inﬂuence
the tumorigenic process, suggesting the putative importance of HOXA9
for GBM development, progression, and aggressiveness [10].3. Discussion
Herein, we describe the transcriptome of HOXA9 in human im-
mortalized astrocytes (hTERT/E6/E7), GBM cell lines (U87MG and
U251MG) and in a patient-derived GBM cell culture (GBML18). These
data include HOXA9-overexpression models (hTERT/E6/E7 and
U87MG) and HOXA9-silencing models (U251MG and GBML18).
HOXA9-overexpression augmented the expression of genes associated
with increased stem-cell characteristics, invasion, migration, and
tumor vasculature, among other cancer hallmarks. Concordantly,
HOXA9-silencing decreased the expression of genes associated with
the same characteristics. Collectively, these data suggests the impor-
tance of HOXA9 in GBM and may explain the poor survival of patients
overexpressing this gene [4,10].Conﬂict of interest
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